K Alexander Papp

Summary

Affiliation: Probity Medical Research
Country: Canada

Publications

  1. ncbi request reprint Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    J Am Acad Dermatol 48:48-54. 2003
  2. pmc The long-term efficacy and safety of new biological therapies for psoriasis
    Kim A Papp
    Probity Medical Research, University of Western Ontario, 135 Union Street East, Waterloo, Ontario, Canada
    Arch Dermatol Res 298:7-15. 2006
  3. ncbi request reprint Efalizumab for the treatment of psoriatic arthritis
    Kim A Papp
    Probity Medical Research, Waterloo, ON, Canada
    J Cutan Med Surg 11:57-66. 2007
  4. ncbi request reprint Psoriasis care: new and emerging pharmacologic trends
    Kim A Papp
    Probity Medical Research, Waterloo, ON
    J Cutan Med Surg 14:119-29. 2010
  5. ncbi request reprint Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies
    Kim Papp
    Probity Medical Research, University of Western Ontario, Waterloo, ON
    J Cutan Med Surg 13:S58-66. 2009
  6. pmc The safety of etanercept for the treatment of plaque psoriasis
    Kim A Papp
    University of Western Ontario, and K Papp Clinical Research Waterloo, ON, Canada
    Ther Clin Risk Manag 3:245-58. 2007
  7. pmc Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
    Vibeke Strand
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
    Health Qual Life Outcomes 11:82. 2013
  8. ncbi request reprint Examining the risk of cardiovascular disease in patients with psoriasis: a critical review
    Kim Papp
    Probity Medical Research, Waterloo, ON
    J Cutan Med Surg 17:89-105. 2013
  9. doi request reprint Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    K A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, ON N2J1C4, Canada
    Br J Dermatol 168:844-54. 2013
  10. doi request reprint Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
    K A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada
    Br J Dermatol 168:412-21. 2013

Detail Information

Publications42

  1. ncbi request reprint Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    J Am Acad Dermatol 48:48-54. 2003
    ..A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product...
  2. pmc The long-term efficacy and safety of new biological therapies for psoriasis
    Kim A Papp
    Probity Medical Research, University of Western Ontario, 135 Union Street East, Waterloo, Ontario, Canada
    Arch Dermatol Res 298:7-15. 2006
    ..Long-term data from psoriasis trials continue to accumulate. Recent data suggest that biological therapies have efficacy and safety profiles suitable for the long-term treatment of patients with moderate to severe psoriasis...
  3. ncbi request reprint Efalizumab for the treatment of psoriatic arthritis
    Kim A Papp
    Probity Medical Research, Waterloo, ON, Canada
    J Cutan Med Surg 11:57-66. 2007
    ..The effect of efalizumab therapy on PsA has not previously been investigated...
  4. ncbi request reprint Psoriasis care: new and emerging pharmacologic trends
    Kim A Papp
    Probity Medical Research, Waterloo, ON
    J Cutan Med Surg 14:119-29. 2010
    ..The guidelines advocate patient-centered psoriasis care in which physicians explore appropriate options to find safe therapies that patients will adhere to and be satisfied with over the long term...
  5. ncbi request reprint Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies
    Kim Papp
    Probity Medical Research, University of Western Ontario, Waterloo, ON
    J Cutan Med Surg 13:S58-66. 2009
    ..Adalimumab, a fully human monoclonal antibody, binds to and neutralizes tumor necrosis factor...
  6. pmc The safety of etanercept for the treatment of plaque psoriasis
    Kim A Papp
    University of Western Ontario, and K Papp Clinical Research Waterloo, ON, Canada
    Ther Clin Risk Manag 3:245-58. 2007
    ..The safe use of etanercept for the treatment of psoriasis requires an appreciation of potential adverse events as well as screening and monitoring strategies designed to manage patient risk...
  7. pmc Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
    Vibeke Strand
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
    Health Qual Life Outcomes 11:82. 2013
    ..Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production...
  8. ncbi request reprint Examining the risk of cardiovascular disease in patients with psoriasis: a critical review
    Kim Papp
    Probity Medical Research, Waterloo, ON
    J Cutan Med Surg 17:89-105. 2013
    ..Increased prevalence of cardiovascular disease (CVD) in psoriasis patients could be due to a greater prevalence of traditional cardiovascular (CV) risk factors or increased inflammatory disease burden...
  9. doi request reprint Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    K A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, ON N2J1C4, Canada
    Br J Dermatol 168:844-54. 2013
    ..Long-term safety evaluations of biologics are needed to inform patient management decisions...
  10. doi request reprint Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
    K A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada
    Br J Dermatol 168:412-21. 2013
    ....
  11. doi request reprint Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
    K A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada
    Br J Dermatol 167:668-77. 2012
    ..Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as a potential treatment for plaque psoriasis...
  12. doi request reprint Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study
    K Papp
    Probity Medical Research, Waterloo, ON, Canada
    J Eur Acad Dermatol Venereol 26:1007-13. 2012
    ..Adalimumab is an effective treatment for chronic plaque psoriasis...
  13. ncbi request reprint Biologic therapy in psoriasis: perspectives on associated risks and patient management
    Kim A Papp
    Probity Medical Research, Waterloo, ON
    J Cutan Med Surg 16:153-68. 2012
    ..Previous publications have described practical considerations for initiating biologic therapy in psoriasis patients. However, most publications have focused on anti-tumor necrosis factor (TNF) therapy...
  14. doi request reprint Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
    Kim Papp
    Probity Medical Research, Waterloo, ON, Canada
    Lancet 380:738-46. 2012
    ..We assessed the clinical efficacy and safety of different doses of apremilast in the treatment of patients with moderate to severe plaque psoriasis...
  15. doi request reprint Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults
    Kim A Papp
    Probity Medical Research Inc, Waterloo, Ontario, Canada
    J Am Acad Dermatol 67:e11-5. 2012
    ..Tacrolimus is a topical calcineurin inhibitor with immunomodulatory, anti-inflammatory, and fungicidal properties that may be beneficial in the treatment of facial seborrheic dermatitis...
  16. doi request reprint Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
    Kim A Papp
    Probity Medical Research, Waterloo, ON, Canada
    N Engl J Med 366:1181-9. 2012
    ....
  17. pmc Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
    Michelle A Lowes
    Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA
    BMC Dermatol 7:2. 2007
    ..Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur...
  18. doi request reprint Monitoring patients treated with efalizumab or alefacept
    K A Papp
    Probity Medical Research, Waterloo, ON, Canada
    Curr Probl Dermatol 38:95-106. 2009
    ..Most important for patients on either therapy is appropriate intermittent clinical evaluations to ensure stable, safe, and effective therapy...
  19. ncbi request reprint Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population
    Kim Papp
    K Papp Clinical Research, Probity Medical Research, Waterloo, ON
    J Cutan Med Surg 14:167-74. 2010
    ..limited data are available on the epidemiologic features of psoriasis in Canada...
  20. doi request reprint Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis
    Kim Papp
    Probity Medical Research Inc, Waterloo, Ontario, Canada
    Curr Med Res Opin 26:2287-300. 2010
    ..Tumor necrosis factor (TNF)-α plays a critical role in psoriasis pathogenesis, and several anti-TNF agents have been developed as therapeutic drugs in this indication...
  21. doi request reprint Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    Clin Drug Investig 31:51-60. 2011
    ..Rates and impacts of worsening symptoms in patients with psoriasis have not been well characterized...
  22. doi request reprint Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
    K Papp
    Probity Medical Research, Waterloo, ON, Canada
    Br J Dermatol 164:434-41. 2011
    ..Adalimumab is effective for moderate to severe chronic plaque psoriasis; however, data regarding retreatment following withdrawal and subsequent relapse are limited...
  23. ncbi request reprint Canadian guidelines for the management of plaque psoriasis: overview
    Kim Papp
    K Papp Clinical Research, Waterloo, ON, Canada
    J Cutan Med Surg 15:210-9. 2011
    ..dermatology.ca/guidelines/cdnpsoriasisguidelines.pdf> (English) or <http://www.dermatology.ca/french/psoriasisguidelines.html> (French)...
  24. ncbi request reprint Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    J Am Acad Dermatol 52:247-53. 2005
    ..We investigated whether treatment of atopic dermatitis with pimecrolimus cream 1% in infants affects the development of a normal antibody response to vaccinations...
  25. doi request reprint Monitoring biologics for the treatment of psoriasis
    Kim A Papp
    Probity Medical Research, University of Western Ontario, 135 Union Street East, Waterloo, ON, Canada N2J 1C4
    Clin Dermatol 26:515-21. 2008
    ..The better risks and benefits are understood, the more precise monitoring guidelines can be defined...
  26. pmc Analytical approaches to reporting long-term clinical trial data
    Kim A Papp
    Probity Medical Research, Waterloo, ON, Canada
    Curr Med Res Opin 24:2001-8. 2008
    ..Therefore, standard analytical strategies used in short-term randomized, controlled trials (intent-to-treat, per-protocol) may not always be appropriate for data generated in long-term studies...
  27. doi request reprint Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    Kim A Papp
    Probity Medical Research, Waterloo and University of Western Ontario, London, ON, Canada
    Lancet 371:1675-84. 2008
    ..This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders...
  28. ncbi request reprint Etanercept in psoriasis
    Kim A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada
    Expert Opin Pharmacother 5:2139-46. 2004
    ..No opportunistic infections, including tuberculosis, were reported. From analysis of the available clinical trials, etanercept appears to be an effective and well-tolerated agent for the treatment of moderate-to-severe psoriasis...
  29. ncbi request reprint Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    Drugs Today (Barc) 40:889-99. 2004
    ..This article reviews the role of T lymphocytes in psoriasis pathogenesis, the mechanism of efalizumab action, and the efficacy and safety data observed during the efalizumab clinical trials...
  30. ncbi request reprint Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study
    Kim A Papp
    Probity Medical Research, Hannover Medical University, Waterloo, Ontario, Canada
    J Am Acad Dermatol 52:240-6. 2005
    ..Pimecrolimus was applied twice daily at the first signs or symptoms of the disease until clearance. Outcome measures included the incidence of adverse events and the Eczema Area and Severity Index (EASI)...
  31. ncbi request reprint Potential future therapies for psoriasis
    K Alexander Papp
    Probity Medical Research, and University of Western Ontario, London, Ontario, Canada
    Semin Cutan Med Surg 24:58-63. 2005
  32. ncbi request reprint A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
    K A Papp
    Probity Medical Research, Waterloo, Ontario N2J 1C4, Canada
    Br J Dermatol 152:1304-12. 2005
    ..In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated...
  33. ncbi request reprint Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    J Am Acad Dermatol 54:S164-70. 2006
    ..Efalizumab targets T cell-mediated steps important in psoriasis immunopathogenesis...
  34. ncbi request reprint Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis
    Kim A Papp
    Probity Medical Research, N2J 1B7, Waterloo, ON
    J Cutan Med Surg 9:26-32. 2006
    ..A growing body of clinical evidence, as well as experience from clinical investigators, has provided much insight into the management strategies for patients undergoing treatment with efalizumab...
  35. ncbi request reprint Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II
    Kim A Papp
    University of Western Ontario, Waterloo, Ont, Canada
    J Cutan Med Surg 9:313-23. 2005
    ..The efficacy and safety of efalizumab have been evaluated in multiple clinical trials...
  36. ncbi request reprint Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    Int J Dermatol 45:605-14. 2006
    ..To provide safety data for efalizumab, a recombinant humanized monoclonal IgG(1) antibody, in adults with chronic plaque psoriasis...
  37. pmc Evaluation of efalizumab using safe psoriasis control
    Kim A Papp
    Probity Medical Research, 135 Union Street East, Waterloo, Ontario, Canada
    BMC Dermatol 6:8. 2006
    ....
  38. pmc Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence
    Kim A Papp
    Probity Medical Research, Waterloo, and University of Western Ontario, Ontario, Canada
    BMC Dermatol 6:9. 2006
    ..This analysis evaluated approaches for managing inflammatory recurrence after discontinuation of efalizumab...
  39. ncbi request reprint Scalp psoriasis: a review of current topical treatment options
    K Papp
    Probity Medical Research Union, Waterloo, Ontario, Canada
    J Eur Acad Dermatol Venereol 21:1151-60. 2007
    ....
  40. doi request reprint Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study
    K Papp
    Probity Medical Research, Waterloo, ON, Canada
    Lancet 371:1337-42. 2008
    ..ISA247, a novel inhibitor, was effective and well tolerated in a phase II study of patients with plaque psoriasis. Therefore its efficacy was assessed in this phase III study...
  41. ncbi request reprint The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody
    K Papp
    Probity Medical Research, 30 Union St East, Waterloo, Ontario N2J 1B7, Canada
    J Am Acad Dermatol 45:665-74. 2001
    ..This study investigated whether treatment with anti-CD11a antibody provides clinical benefit to patients with moderate to severe plaque psoriasis...
  42. ncbi request reprint Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    J Cutan Med Surg 9:276-83. 2005
    ..PASI is an inadequate outcome measure for the assessment of psoriasis treatments. No currently used endpoints provide a benefit: risk assessment of treatment taking into consideration all available efficacy and safety data...